CYTOKINETICS, INCORPORATED License and Services Revenue (Deprecated 2018-01-31)
CYTOKINETICS, INCORPORATED (CYTK) reported License and Services Revenue (Deprecated 2018-01-31) of $1.68 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Income Statement › Other Income
us-gaap:LicenseAndServicesRevenue · last filed 2018-05-10
- CYTOKINETICS, INCORPORATED license and services revenue (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $1.68M, a 16.39% increase year-over-year.
- CYTOKINETICS, INCORPORATED license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $2.09M, a 34.90% decline year-over-year.
- CYTOKINETICS, INCORPORATED license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $318.00K, a 99.40% decline year-over-year.
- CYTOKINETICS, INCORPORATED license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $4.94M, a 153.44% increase year-over-year.
- CYTOKINETICS, INCORPORATED license and services revenue (deprecated 2018-01-31) for fiscal 2017 was $8.80M, a 85.85% decline from fiscal 2016.
- CYTOKINETICS, INCORPORATED license and services revenue (deprecated 2018-01-31) for fiscal 2016 was $62.17M, a 346.69% increase from fiscal 2015.
- CYTOKINETICS, INCORPORATED license and services revenue (deprecated 2018-01-31) for fiscal 2015 was $13.92M, a 41.50% increase from fiscal 2014.
- CYTOKINETICS, INCORPORATED license and services revenue (deprecated 2018-01-31) for fiscal 2014 was $9.84M, a 155.35% increase from fiscal 2013.
| Period end | License and Services Revenue (Deprecated 2018-01-31) 3 month | License and Services Revenue (Deprecated 2018-01-31) 6 month | License and Services Revenue (Deprecated 2018-01-31) 9 month | License and Services Revenue (Deprecated 2018-01-31) 12 month | License and Services Revenue (Deprecated 2018-01-31) 12 month as first filed | License and Services Revenue (Deprecated 2018-01-31) 194 month |
|---|---|---|---|---|---|---|
| 2018-03-31 | $1.68M 10-Q · filed 2018-05-10 | $3.78M derived: sum of 2 quarters · filed 2018-05-10 | $4.09M derived: sum of 3 quarters · filed 2018-05-10 | $9.04M derived: sum of 4 quarters · filed 2018-05-10 | ||
| 2017-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $2.41M derived: sum of 2 quarters · filed 2018-03-05 | $7.35M derived: sum of 3 quarters · filed 2018-03-05 | $8.80M 10-K · filed 2018-03-05 | ||
| 2017-09-30 | $318.00K 10-Q · filed 2017-11-03 | $5.26M derived: sum of 2 quarters · filed 2017-11-03 | $6.71M 10-Q · filed 2017-11-03 | $9.92M derived: sum of 4 quarters · filed 2018-05-10 | ||
| 2017-06-30 | $4.94M 10-Q · filed 2017-08-04 | $6.39M 10-Q · filed 2017-08-04 | $9.60M derived: sum of 3 quarters · filed 2018-05-10 | $62.64M derived: sum of 4 quarters · filed 2018-05-10 | ||
| 2017-03-31 | $1.45M 10-Q · filed 2018-05-10 | $4.66M derived: sum of 2 quarters · filed 2018-05-10 | $57.69M derived: sum of 3 quarters · filed 2018-05-10 | $59.64M derived: sum of 4 quarters · filed 2018-05-10 | ||
| 2016-12-31 | $3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $56.25M derived: sum of 2 quarters · filed 2018-03-05 | $58.20M derived: sum of 3 quarters · filed 2018-03-05 | $62.17M 10-K · filed 2018-03-05 | $0.00 10-K · filed 2017-03-06 | |
| 2016-09-30 | $53.03M 10-Q · filed 2017-11-03 | $54.98M derived: sum of 2 quarters · filed 2017-11-03 | $58.96M 10-Q · filed 2017-11-03 | |||
| 2016-06-30 | $1.95M 10-Q · filed 2017-08-04 | $5.92M 10-Q · filed 2017-08-04 | ||||
| 2015-12-31 | $13.92M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $13.92M derived: sum of 2 quarters · filed 2018-03-05 | $13.92M derived: sum of 3 quarters · filed 2018-03-05 | $13.92M 10-K · filed 2018-03-05 | $0.00 10-K · filed 2016-03-03 | |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-05 | $0.00 derived: sum of 2 quarters · filed 2015-11-05 | $0.00 10-Q · filed 2015-11-05 | $2.27M derived: sum of 4 quarters · filed 2017-03-06 | ||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-05 | $0.00 10-Q · filed 2015-08-05 | $2.27M derived: sum of 3 quarters · filed 2017-03-06 | $5.00M derived: sum of 4 quarters · filed 2017-03-06 | ||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-04 | $2.27M derived: sum of 2 quarters · filed 2017-03-06 | $5.00M derived: sum of 3 quarters · filed 2017-03-06 | $7.75M derived: sum of 4 quarters · filed 2017-03-06 | ||
| 2014-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $5.00M derived: sum of 2 quarters · filed 2017-03-06 | $7.75M derived: sum of 3 quarters · filed 2017-03-06 | $9.84M 10-K · filed 2017-03-06 | ||
| 2014-09-30 | $2.73M 10-Q · filed 2015-11-05 | $5.48M derived: sum of 2 quarters · filed 2015-11-05 | $7.57M 10-Q · filed 2015-11-05 | $10.01M derived: sum of 4 quarters · filed 2016-03-03 | ||
| 2014-06-30 | $2.75M 10-Q · filed 2015-08-05 | $4.83M 10-Q · filed 2015-08-05 | $7.27M derived: sum of 3 quarters · filed 2016-03-03 | $8.68M derived: sum of 4 quarters · filed 2016-03-03 | ||
| 2014-03-31 | $2.08M 10-Q · filed 2015-05-04 | $4.52M derived: sum of 2 quarters · filed 2016-03-03 | $5.93M derived: sum of 3 quarters · filed 2016-03-03 | |||
| 2013-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $3.85M derived: sum of 2 quarters · filed 2016-03-03 | $3.85M 10-K · filed 2016-03-03 | |||
| 2013-09-30 | $1.41M 10-Q · filed 2014-11-06 | $1.41M 10-Q · filed 2014-11-06 | $1.41M 10-Q · filed 2013-11-06 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |